Mariia Oliinyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mariia Oliinyk has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Larysa Zhuravlyova
Харківський національний медичний університет
4 shared publications - Yu. K. Sikalo
Kharkiv National Medical University
4 shared publications - V. O. Fedorov
Харківський національний медичний університет
2 shared publications Ю. К. Сікало
Харківський національний медичний університет
2 shared publications- A. K. Zhuravlyova
Харківський національний медичний університет
1 shared publication - Anne Karien C. A. Marijnissen
Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1) , rkag015
Exploring cardiovascular risk management implementation in Dutch rheumatoid arthritis patients: insights from rheumatologists and patients
Objectives: To explore the implementation of cardiovascular risk management (CVRM) in Dutch RA patients from the perspective of rheumatologists and patients. Methods: An online survey was conducted among Dutch rheumatologists, rheumatology physician assistants (PAs) and RA patients. Healthcare providers completed a 37-item adapted version of the Determinants of Implementation Behavior Questionnaire to assess various aspects of CVRM implementation behaviour on a 7-point Likert scale. Simultaneously, a 13-item questionnaire was administered to RA patients to gather experiences related to CVRM. Data for both surveys were collected online between 23 September and 1 December 2024. Results: A total of 85 healthcare providers [93% rheumatologists, mean age 47.2 years (s.d. 8.8), 72% female] and 145 RA patients [mean age 58 years (s.d. 12.6), 89% female] completed the survey. Providers did not seem to lack (self-reported) knowledge on CVRM, yet significant implementation challenges were identified across several domains, including skills, professional roles and beliefs about capabilities. Time constraints, limited resources, insufficient financial support and the absence of local protocols were cited as major barriers. From the patient perspective, only 39% reported being informed about RA-related cardiovascular risks, mostly by rheumatologists. Rheumatologists frequently provided guidance on physical activity (21%), while general practitioners were more active in managing traditional cardiovascular risk factors, prescribing medications (23%) and offering self-management advice (16%). Conclusion: Our study highlights the main challenges in implementing CVRM in daily practice, indicating the need for the development of targeted strategies to overcome these barriers.
- 2 January 2026
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 10 (1) , rkag015
Open AccessExploring cardiovascular risk management implementation in Dutch rheumatoid arthritis patients: insights from rheumatologists and patients
Objectives: To explore the implementation of cardiovascular risk management (CVRM) in Dutch RA patients from the perspective of rheumatologists and patients. Methods: An online survey was conducted among Dutch rheumatologists, rheumatology physician assistants (PAs) and RA patients. Healthcare providers completed a 37-item adapted version of the Determinants of Implementation Behavior Questionnaire to assess various aspects of CVRM implementation behaviour on a 7-point Likert scale. Simultaneously, a 13-item questionnaire was administered to RA patients to gather experiences related to CVRM. Data for both surveys were collected online between 23 September and 1 December 2024. Results: A total of 85 healthcare providers [93% rheumatologists, mean age 47.2 years (s.d. 8.8), 72% female] and 145 RA patients [mean age 58 years (s.d. 12.6), 89% female] completed the survey. Providers did not seem to lack (self-reported) knowledge on CVRM, yet significant implementation challenges were identified across several domains, including skills, professional roles and beliefs about capabilities. Time constraints, limited resources, insufficient financial support and the absence of local protocols were cited as major barriers. From the patient perspective, only 39% reported being informed about RA-related cardiovascular risks, mostly by rheumatologists. Rheumatologists frequently provided guidance on physical activity (21%), while general practitioners were more active in managing traditional cardiovascular risk factors, prescribing medications (23%) and offering self-management advice (16%). Conclusion: Our study highlights the main challenges in implementing CVRM in daily practice, indicating the need for the development of targeted strategies to overcome these barriers.
- Open Access
- 31 March 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 65-76
Managing a patient with rapidly progressive methotrexate-resistant localized scleroderma (morphea). Clinical case
Localized scleroderma (Morphea) is a chronic autoimmune connective tissue disease characterized by fibrosis of the skin and underlying tissues, which may lead to disability and cosmetic problems. The disease usually lacks systemic manifestations such as internal organ involvement, Raynaud’s phenomenon, or telangiectasia. In rare cases, morphea progresses rapidly, is resistant to standard therapy, and requires alternative treatment methods. The aim of the article is to enhance physicians’ awareness regarding the latest advancements in understanding the diverse clinical variants of morphea, with a focus on therapeutic strategies and their effectiveness within the context of an individualized treatment approach. The article presents modern approaches to understanding the pathogenesis and clinical variability of morphea, emphasizing diagnostic difficulties and features of the choice of therapeutic strategy in rheumatological practice. Particular attention is paid to treatment options that go beyond traditional therapy, particularly the use of immunobiological agents. The role of a multidisciplinary approach in the management of such patients, which includes the cooperation of rheumatologists, dermatologists, and other specialists, is also highlighted. We present a case of a 51‑year‑old patient with rapidly progressive morphea, resistant to methotrexate. The initial symptoms included erythematous spots, skin induration, and swelling of the lower extremities, which later spread to the upper extremities, despite 1.5 years of therapy with methotrexate (15 mg/week) and methylprednisolone (8 mg/day). Physical examination revealed widespread induration and hyperpigmentation in 4 of the 7 body zones without signs of systemic organ damage. A biopsy confirmed the diagnosis of localized scleroderma (morphea), clinically defined as a generalized form, active phase, stage II (modified Rodnan skin score=18, Localized Scleroderma Skin Damage Index=47, Modified Localized Scleroderma Skin Activity Index=44, general assessment of the patient’s condition by the doctor (PGA)=70). Methotrexate was replaced with mycophenolate mofetil (500 mg twice a day with further intensification) in combination with low doses of methylprednisolone (4 mg/day), which after 2 months halted disease progression. This case highlights the variability of the clinical course of morphea and underscores the importance of careful clinical observation, timely diagnosis, and individualized approach to the treatment of such patients, as well as the need for further research to optimize therapeutic strategies for this pathology. The presented modern data will help to raise awareness of physicians about the variety of clinical manifestations of morphea and the possibilities of using alternative treatments.
- 31 March 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 65-76
Open AccessManaging a patient with rapidly progressive methotrexate-resistant localized scleroderma (morphea). Clinical case
Localized scleroderma (Morphea) is a chronic autoimmune connective tissue disease characterized by fibrosis of the skin and underlying tissues, which may lead to disability and cosmetic problems. The disease usually lacks systemic manifestations such as internal organ involvement, Raynaud’s phenomenon, or telangiectasia. In rare cases, morphea progresses rapidly, is resistant to standard therapy, and requires alternative treatment methods. The aim of the article is to enhance physicians’ awareness regarding the latest advancements in understanding the diverse clinical variants of morphea, with a focus on therapeutic strategies and their effectiveness within the context of an individualized treatment approach. The article presents modern approaches to understanding the pathogenesis and clinical variability of morphea, emphasizing diagnostic difficulties and features of the choice of therapeutic strategy in rheumatological practice. Particular attention is paid to treatment options that go beyond traditional therapy, particularly the use of immunobiological agents. The role of a multidisciplinary approach in the management of such patients, which includes the cooperation of rheumatologists, dermatologists, and other specialists, is also highlighted. We present a case of a 51‑year‑old patient with rapidly progressive morphea, resistant to methotrexate. The initial symptoms included erythematous spots, skin induration, and swelling of the lower extremities, which later spread to the upper extremities, despite 1.5 years of therapy with methotrexate (15 mg/week) and methylprednisolone (8 mg/day). Physical examination revealed widespread induration and hyperpigmentation in 4 of the 7 body zones without signs of systemic organ damage. A biopsy confirmed the diagnosis of localized scleroderma (morphea), clinically defined as a generalized form, active phase, stage II (modified Rodnan skin score=18, Localized Scleroderma Skin Damage Index=47, Modified Localized Scleroderma Skin Activity Index=44, general assessment of the patient’s condition by the doctor (PGA)=70). Methotrexate was replaced with mycophenolate mofetil (500 mg twice a day with further intensification) in combination with low doses of methylprednisolone (4 mg/day), which after 2 months halted disease progression. This case highlights the variability of the clinical course of morphea and underscores the importance of careful clinical observation, timely diagnosis, and individualized approach to the treatment of such patients, as well as the need for further research to optimize therapeutic strategies for this pathology. The presented modern data will help to raise awareness of physicians about the variety of clinical manifestations of morphea and the possibilities of using alternative treatments.
- Open Access
- 19 March 2025
- Published by SAGE Publications in CARTILAGE
Comparing Five Major Knee Osteoarthritis Cohort Studies: Similarities, Differences, and Unique Aspects of CHECK, OAI, FNIH, IMI-APPROACH, and MOST
Objective: To analyze and synthesize the information available from five pivotal, large-scale, multicenter, observational studies (CHECK, OAI, FNIH Biomarkers Consortium, IMI-APPROACH, and MOST) focusing on knee osteoarthritis (OA), which can be used to elucidate disease progression, risk factors, and the effectiveness of potential interventions. Design: For this narrative review, a comprehensive literature search and data extraction from official web pages and scientific databases were conducted to compare methodologies, in- and exclusion criteria, outcomes, and cohort characteristics across the studies. Thematic, comparative, and qualitative analyses were employed to identify trends, commonalities, and disparities among the findings. Results: The studies collectively enhanced understanding of the onset and progression of knee OA, and in several of the studies, hip OA, emphasizing the importance of both systemic and local risk factors. Advanced imaging and biomarkers are important components in all the cohorts, with the goal of aiding early diagnosis and tracking disease progression. All cohorts evaluated unique markers generally not available in the other cohorts, while other factors overlap, suggesting possibilities for combining or cross-validating between cohorts. Conclusions: The collaborative efforts of major OA research significantly advance our understanding of knee OA. These studies highlight the importance of a multifaceted approach, integrating advanced imaging, biomarkers, and longitudinal data to tackle the complexities of OA. By synthesizing findings and addressing knowledge gaps such as heterogeneity of patients and used measurements, and use of novel pain measures, future research can develop more effective diagnostic tools and treatments, ultimately enhancing the quality of life for OA patients.
- 19 March 2025
- Published by SAGE Publications in CARTILAGE
Open AccessComparing Five Major Knee Osteoarthritis Cohort Studies: Similarities, Differences, and Unique Aspects of CHECK, OAI, FNIH, IMI-APPROACH, and MOST
Objective: To analyze and synthesize the information available from five pivotal, large-scale, multicenter, observational studies (CHECK, OAI, FNIH Biomarkers Consortium, IMI-APPROACH, and MOST) focusing on knee osteoarthritis (OA), which can be used to elucidate disease progression, risk factors, and the effectiveness of potential interventions. Design: For this narrative review, a comprehensive literature search and data extraction from official web pages and scientific databases were conducted to compare methodologies, in- and exclusion criteria, outcomes, and cohort characteristics across the studies. Thematic, comparative, and qualitative analyses were employed to identify trends, commonalities, and disparities among the findings. Results: The studies collectively enhanced understanding of the onset and progression of knee OA, and in several of the studies, hip OA, emphasizing the importance of both systemic and local risk factors. Advanced imaging and biomarkers are important components in all the cohorts, with the goal of aiding early diagnosis and tracking disease progression. All cohorts evaluated unique markers generally not available in the other cohorts, while other factors overlap, suggesting possibilities for combining or cross-validating between cohorts. Conclusions: The collaborative efforts of major OA research significantly advance our understanding of knee OA. These studies highlight the importance of a multifaceted approach, integrating advanced imaging, biomarkers, and longitudinal data to tackle the complexities of OA. By synthesizing findings and addressing knowledge gaps such as heterogeneity of patients and used measurements, and use of novel pain measures, future research can develop more effective diagnostic tools and treatments, ultimately enhancing the quality of life for OA patients.
- Open Access
- 30 December 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 4,p. 48-55
Rheumatoid arthritis and viral hepatitis. Tactics of a rheumatologist. Literature review
Rheumatoid arthritis (RA) is an autoimmune disease that can be accompanied by complex liver involvement. The diagnosis and differentiation of these conditions are often complicated by the rarity of liver biopsies and the similarity of symptoms to other liver diseases. Viral hepatitis B and C in the context of rheumatoid arthritis can mimic rheumatological manifestations, further complicating timely diagnosis and worsening the prognosis for patients with rheumatoid arthritis. This literature review aims to systematize knowledge and assess the risks associated with the treatment of rheumatoid arthritis in patients with viral hepatitis B and C. Additionally, the article aims to provide recommendations for screening and treatment of viral hepatitis in these patients. The review is based on the analysis of available literature for the last ten years, including clinical trials, meta‑analyses, systematic reviews, and recommendations for the treatment of viral hepatitis in patients with rheumatoid arthritis. According to the literature, liver involvement in patients with rheumatoid arthritis can be caused by the disease itself, its treatment, or viral infections. Research results emphasize the importance of regular monitoring of liver function and screening for viral hepatitis B and C before starting rheumatoid arthritis treatment and during the use of immunosuppressive drugs. The integration of screening for viral hepatitis B and C into standard medical protocols for patients with rheumatoid arthritis before starting immunosuppressive therapy is essential. The timely detection of these infections is crucial because the treatment of hepatitis and immunosuppressive therapy for rheumatoid arthritis are interconnected and require a comprehensive approach. Adaptation of treatment depending on the status of viral infection is necessary to minimize liver risks and optimize the outcomes of rheumatoid arthritis treatment.
- 30 December 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 4,p. 48-55
Open AccessRheumatoid arthritis and viral hepatitis. Tactics of a rheumatologist. Literature review
Rheumatoid arthritis (RA) is an autoimmune disease that can be accompanied by complex liver involvement. The diagnosis and differentiation of these conditions are often complicated by the rarity of liver biopsies and the similarity of symptoms to other liver diseases. Viral hepatitis B and C in the context of rheumatoid arthritis can mimic rheumatological manifestations, further complicating timely diagnosis and worsening the prognosis for patients with rheumatoid arthritis. This literature review aims to systematize knowledge and assess the risks associated with the treatment of rheumatoid arthritis in patients with viral hepatitis B and C. Additionally, the article aims to provide recommendations for screening and treatment of viral hepatitis in these patients. The review is based on the analysis of available literature for the last ten years, including clinical trials, meta‑analyses, systematic reviews, and recommendations for the treatment of viral hepatitis in patients with rheumatoid arthritis. According to the literature, liver involvement in patients with rheumatoid arthritis can be caused by the disease itself, its treatment, or viral infections. Research results emphasize the importance of regular monitoring of liver function and screening for viral hepatitis B and C before starting rheumatoid arthritis treatment and during the use of immunosuppressive drugs. The integration of screening for viral hepatitis B and C into standard medical protocols for patients with rheumatoid arthritis before starting immunosuppressive therapy is essential. The timely detection of these infections is crucial because the treatment of hepatitis and immunosuppressive therapy for rheumatoid arthritis are interconnected and require a comprehensive approach. Adaptation of treatment depending on the status of viral infection is necessary to minimize liver risks and optimize the outcomes of rheumatoid arthritis treatment.
- Open Access
- 27 January 2023
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Pathologia
- Vol. 19 (3) , 256-262
Clinical case of atypical course of Crohn’s disease
Хвороба Крона (ХК) – хронічне рецидивне запальне захворювання кишечника з широкою варіабельністю клінічних проявів; може перебігати і за класичними шлунково-кишковими фенотипами, і з переважанням позакишкових ознак. Атиповий перебіг ХК спостерігають відносно часто, він є проявом ураження майже всіх систем організму, включаючи гепатобіліарну, імунну, кровотворну, серцево-судинну, нервову, а також уражає очі, шкіру, легені та нирки. Атипова маніфестація часто передує кишковим проявам, що ускладнює встановлення діагнозу. Різноманітні клінічні прояви ХК, часто нетиповий перебіг, а також відсутність стандартизованих критеріїв діагностики можуть стати перепоною для лікарів на шляху вчасного виявлення хвороби й ефективного лікування. Мета роботи – описати клінічний випадок діагностично складного пацієнта нашої клініки з атиповим перебігом ХК та ускладненнями, несумісними з життям; висвітлити проблему моніторингу та можливі шляхи вирішення. Результати. В наведеному клінічному випадку описано пацієнта ревматологічного відділення КНП «Обласна клінічна лікарня» ХОР (м. Харків) з атиповим перебігом ХК, переважними проявами ураження нервової та судинної систем. Під час перебування у стаціонарі пацієнтові здійснили повний спектр діагностичних тестів, він проконсультований суміжними спеціалістами, однак прямих даних про запальне захворювання кишківника не отримали. Неможливість виконати колоноскопію з біопсією, що пов’язана з тяжкістю стану пацієнта, відтермінувала вчасне діагностування ХК і зумовила виникнення ускладнень, несумісних з життям. Діагноз встановили посмертно. Хворий помер внаслідок інтоксикації, що спричинена ускладненням ХК, а саме перфорацією кишки, проривом міжкишкового абсцесу, виникненням перитоніту, септицемії. Висновки. ХК – складна міждисциплінарна проблема, і вкрай важливим є вивчення лікарями варіантів атипової маніфестації та перебігу запальних захворювань кишківника, методів їх оцінювання та шляхів ефективного менеджменту. В цьому кейсі наведено останні епідеміологічні дані щодо поширеності атипових проявів ХК, визначено ключові напрями діагностичного пошуку в складного пацієнта.
- 27 January 2023
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Pathologia
- Vol. 19 (3) , 256-262
Open AccessClinical case of atypical course of Crohn’s disease
Хвороба Крона (ХК) – хронічне рецидивне запальне захворювання кишечника з широкою варіабельністю клінічних проявів; може перебігати і за класичними шлунково-кишковими фенотипами, і з переважанням позакишкових ознак. Атиповий перебіг ХК спостерігають відносно часто, він є проявом ураження майже всіх систем організму, включаючи гепатобіліарну, імунну, кровотворну, серцево-судинну, нервову, а також уражає очі, шкіру, легені та нирки. Атипова маніфестація часто передує кишковим проявам, що ускладнює встановлення діагнозу. Різноманітні клінічні прояви ХК, часто нетиповий перебіг, а також відсутність стандартизованих критеріїв діагностики можуть стати перепоною для лікарів на шляху вчасного виявлення хвороби й ефективного лікування. Мета роботи – описати клінічний випадок діагностично складного пацієнта нашої клініки з атиповим перебігом ХК та ускладненнями, несумісними з життям; висвітлити проблему моніторингу та можливі шляхи вирішення. Результати. В наведеному клінічному випадку описано пацієнта ревматологічного відділення КНП «Обласна клінічна лікарня» ХОР (м. Харків) з атиповим перебігом ХК, переважними проявами ураження нервової та судинної систем. Під час перебування у стаціонарі пацієнтові здійснили повний спектр діагностичних тестів, він проконсультований суміжними спеціалістами, однак прямих даних про запальне захворювання кишківника не отримали. Неможливість виконати колоноскопію з біопсією, що пов’язана з тяжкістю стану пацієнта, відтермінувала вчасне діагностування ХК і зумовила виникнення ускладнень, несумісних з життям. Діагноз встановили посмертно. Хворий помер внаслідок інтоксикації, що спричинена ускладненням ХК, а саме перфорацією кишки, проривом міжкишкового абсцесу, виникненням перитоніту, септицемії. Висновки. ХК – складна міждисциплінарна проблема, і вкрай важливим є вивчення лікарями варіантів атипової маніфестації та перебігу запальних захворювань кишківника, методів їх оцінювання та шляхів ефективного менеджменту. В цьому кейсі наведено останні епідеміологічні дані щодо поширеності атипових проявів ХК, визначено ключові напрями діагностичного пошуку в складного пацієнта.
- Open Access
- 14 September 2021
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 77 (3) , 111-119
FEATURES OF MANAGEMENT IN PATIENTS WITH OSTEOPOROSIS AND DIABETES MELLITUS
The number of patients with diabetes mellitus in the world has been progressively increasing in recent years, therefore, the fight against complications of diabetes mellitus is an important problem of our time. The purpose of our review is to analyze the literature data on the risks of osteoporosis in patients with diabetes mellitus, effective diagnostic methods, as well as current recommendations for the treatment and prevention of osteoporosis in this category of patients. Results. We have processed and analyzed literary sources and internationalrecommendations, which identify the main mechanisms and risk factors that contribute to the development of osteoporosis in patients with type 1 and 2 diabetes mellitus; methods for the timely diagnosis of osteoporosis are indicated, methods for correcting the condition of patients with diabetes mellitus, which can help prevent the development of osteoporosis in this group of patients, are given. The current recommendations for the treatment of osteoporosis in men and women are presented. Conclusions. Taking into account the data of the analysis of literary sources, osteoporosis can be considered one of the complications of diabetes mellitus. Today, densitometry and fracture risk assessment FRAX are quite sensitive methods for early diagnosis of osteoporosis in patients with type 1 diabetes mellitus, but not sufficient for patients with type 2 diabetes mellitus, therefore there is a need to determine the trabecular bone index during densitometry, as well as additional actions when assessing the risk of fractures on the FRAX scale. Therapy of patients with osteoporosis with concomitant diabetes mellitus should be based on the achievement of target glycemic levels and the use of bisphosphonates with target level of calcium and vitamin D.
- 14 September 2021
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 77 (3) , 111-119
Open AccessFEATURES OF MANAGEMENT IN PATIENTS WITH OSTEOPOROSIS AND DIABETES MELLITUS
The number of patients with diabetes mellitus in the world has been progressively increasing in recent years, therefore, the fight against complications of diabetes mellitus is an important problem of our time. The purpose of our review is to analyze the literature data on the risks of osteoporosis in patients with diabetes mellitus, effective diagnostic methods, as well as current recommendations for the treatment and prevention of osteoporosis in this category of patients. Results. We have processed and analyzed literary sources and internationalrecommendations, which identify the main mechanisms and risk factors that contribute to the development of osteoporosis in patients with type 1 and 2 diabetes mellitus; methods for the timely diagnosis of osteoporosis are indicated, methods for correcting the condition of patients with diabetes mellitus, which can help prevent the development of osteoporosis in this group of patients, are given. The current recommendations for the treatment of osteoporosis in men and women are presented. Conclusions. Taking into account the data of the analysis of literary sources, osteoporosis can be considered one of the complications of diabetes mellitus. Today, densitometry and fracture risk assessment FRAX are quite sensitive methods for early diagnosis of osteoporosis in patients with type 1 diabetes mellitus, but not sufficient for patients with type 2 diabetes mellitus, therefore there is a need to determine the trabecular bone index during densitometry, as well as additional actions when assessing the risk of fractures on the FRAX scale. Therapy of patients with osteoporosis with concomitant diabetes mellitus should be based on the achievement of target glycemic levels and the use of bisphosphonates with target level of calcium and vitamin D.
- 1 June 2017
- No. 267,p. 114-119
CLINICAL AND GENETIC PECULIARITIES OF VASCULAR MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME (CASE REPORT).
Pathogenetic mechanisms of the development of antiphospholipid syndrome (APS) are considered in the article, which is the basis for the development of clinical manifestations and laboratory markers of APS. The modern literature data are analyzed, according to which the presence of antiphospholipid antibodies is a hypercoagulable background, and the formation of thrombi occurs under the influence of other allowing procoagulation factors. The classification of the main types of hereditary thrombophilia is given, which is the primary disorder, against the background of which an autoimmune thrombosis APS develops. A clinical observation of a young age patient is given, whose heterozygous carriage of mutations in the genes responsible for blood coagulation (F7, PAI-1 and ITGB3-β-integrin), as well as homozygous carriage of a mutation in the MTRR gene associated with a violation of homocysteine methylation, APS was developed, which led to the processes of thrombosis. Timely diagnosis and individually developed pathogenetic therapy allow avoiding life-threatening complications of APS and improving the patients' quality of life. A conclusion about the need for APS and hereditary thrombophilias' examination to all patients of young age with unprovoked thrombosis of deep veins of lower extremities and PE was made.
- 1 June 2017
- No. 267,p. 114-119
CLINICAL AND GENETIC PECULIARITIES OF VASCULAR MANIFESTATIONS OF ANTIPHOSPHOLIPID SYNDROME (CASE REPORT).
Pathogenetic mechanisms of the development of antiphospholipid syndrome (APS) are considered in the article, which is the basis for the development of clinical manifestations and laboratory markers of APS. The modern literature data are analyzed, according to which the presence of antiphospholipid antibodies is a hypercoagulable background, and the formation of thrombi occurs under the influence of other allowing procoagulation factors. The classification of the main types of hereditary thrombophilia is given, which is the primary disorder, against the background of which an autoimmune thrombosis APS develops. A clinical observation of a young age patient is given, whose heterozygous carriage of mutations in the genes responsible for blood coagulation (F7, PAI-1 and ITGB3-β-integrin), as well as homozygous carriage of a mutation in the MTRR gene associated with a violation of homocysteine methylation, APS was developed, which led to the processes of thrombosis. Timely diagnosis and individually developed pathogenetic therapy allow avoiding life-threatening complications of APS and improving the patients' quality of life. A conclusion about the need for APS and hereditary thrombophilias' examination to all patients of young age with unprovoked thrombosis of deep veins of lower extremities and PE was made.